Skip to main content Back to Top

Official Cardiovascular Support for Updating your iPAD (interest in Peripheral Arterial Disease): Risk Factor Management


Subscribe on iTune PodcastsListen on Google PlaySubscribe to Stitcher PodcastsListen on SpotifySubscribe to TuneIn PodcastsSubscribe to iHeartRadio

This podcast series will highlight the recommended approach to managing patients with peripheral arterial disease from screening to therapy selection. Appropriate risk factor modification and therapy is essential in PAD to optimize care by reducing cardiovascular morbidity and mortality.


Zachary StacyZachary Stacy, Pharm.D., BCPS, FCCP, is a clinical pharmacist at the Barnes Jewish West County Hospital.

Dr. Stacy earned his Bachelor of Science degrees in Chemistry and Biology from Blackburn College in Carlinville, Illinois, and his Master of Science degree in Chemistry from Southern Illinois University in Edwardsville, Illinois. Dr. Stacy completed his Doctor of Pharmacy degree at the St. Louis College of Pharmacy and a specialty residency in internal medicine at St. Luke’s Hospital in Chesterfield, Missouri. 

Dr. Stacy’s primary research interests include the prevention of venous thromboembolism and the management of peripheral arterial disease. Dr. Stacy’s didactic responsibilities include ischemic heart disease, heart failure, peripheral arterial disease, and venous thromboembolism. He teaches in the Physician Assistant program at Saint Louis University and the Dental Hygienist program at St. Louis Community College.

Dr. Stacy has won numerous teaching awards including the 2005 Excellence in Clinical Precepting, the 2009 Joe E. Haberle Outstanding Educator of the Year Award, 2009 Emerson Excellence in Teaching Award, and the 2010 Missouri Pharmacy Association Faculty Member of the Year Award. He has authored numerous articles, reviews, and book chapters and frequently provides presentations at state, national, and international conferences. He is an active member of numerous pharmacy organizations including ACCP and ASHP. In 2013, Dr. Stacy was named a Fellow of the American College of Clinical Pharmacy.

Relevant Financial Relationship Disclosure

No relevant financial relationship with an ineligible company.*
*As defined by the Standards of Integrity and Independence definition of ineligible company. 


Paul DobeshPaul P. Dobesh, Pharm.D., FCCP, BCPS, BCCP, Bachelor of Science in Pharmacy from South Dakota State University. Two year add-on Pharm.D. degree also from South Dakota State University. Internal Medicine Specialty Residency with the University of Texas at Austin at Brackenridge Hospital. He is currently Professor of Pharmacy Practice and Science with the University of Nebraska Medical Center College of Pharmacy in Omaha, Nebraska.

Currently maintains clinical practice with cardiology services at Nebraska Medical Center. Responsible for teaching pharmacy and physician assistant students, as well as pharmacy and medical residents. Lectures in the area of ischemic heart disease, antithrombotic therapy, and other cardiology and critical care topics.

Dr. Dobesh has conducted research on antithrombotic therapy, focusing on real-world utilization and health-economics. He has also published over 100 manuscripts and book chapters in these areas. Dr. Dobesh was awarded the “Distinguished Educator or the Year” award at the University of Nebraska Medical Center College of Pharmacy in 2020, an award he has received 6 times since 2007. In 2021 and 2013 he was also awarded the University of Nebraska Medical Center campus wide Outstanding Educator Award.

Relevant Financial Relationship Disclosure with an Ineligible Company*

  • Consultant, Pfizer/BMS Alliance
  • Consultant, Janssen Pharmaceuticals

All of the relevant financial relationships have been mitigated.
*As defined by the Standards of Integrity and Independence definition of ineligible company.

All others in control of the content of this activity do not have a relevant financial relationship (RFR) with an ineligible company.

This podcast is provided by ASHP and sponsored by Janssen Pharmaceuticals, Inc.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.